Indeed, Cell Surface Capture technology highlighted that high CD157 expression levels discriminates tumor cells from normal B cell populations that are CD157-negative, and may serve as an additional marker to improve residual leukemia cell detection and quantification at early treatment time points [70]. This evidence concerns the gene BST1 and leukemia.